Navigation Links
Aethlon Medical Announces Washington, DC Shareholder Presentation
Date:12/20/2010

ral load reduction at the outset of standard of care drug regimens.  
  • Human Immunodeficiency Virus (HIV):  Provides a potential therapeutic option for HIV-infected individuals to manage disease progression once they become resistant to antiviral drug regimens.
  • Bioterror and Pandemic Threats:  Represents the most advanced broad-spectrum strategy to address untreatable bioterror and emerging pandemic threats.

  • The Hemopurifier® is an expansive multi-patented platform technology whose mechanism of action can be leveraged to provide therapeutic, diagnostic, and biomarker discovery solutions. As a therapeutic, the Hemopurifier® is a single-use disposable cartridge designed for implementation within the established infrastructure of dialysis machines and other blood circulatory pumps already located in hospitals and clinics worldwide.

    In design, our Hemopurifier® is a selective filtration device containing affinity agents that tightly bind to high-mannose structures unique to the surface of exosomes produced by cancer and glycoproteins residing on the envelope of viruses. These agents are immobilized around approximately 2800 porous hollow fibers that run the interior length of our device. The resulting design provides us the novel ability to separate both exosome and viral targets away from blood cells so they can then be selectively and permanently removed from the circulatory system. In application, blood circulation is established into the Hemopurifier® via a catheter or other blood access device. Once blood flow has been established, treatment benefit is immediate as the entire circulatory system can pass through the Hemopurifier® in as little as 15 minutes.

    Our wholly owned subsidiary, Exosome Sciences, Inc. (ESI) is focused on the development of exosome-targeted products and services that improve cancer diagnosis, provide post-treatment cancer surveillance, and aid in the discove
    '/>"/>

    SOURCE Aethlon Medical, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4

    Related biology technology :

    1. Aethlon Medical Appoints Jeff Schorey and Wayne Comper to Exosome Sciences Advisory Board
    2. Aethlon Medical to Present at LD MICRO Conference on December 3, 2009
    3. Aethlon Medical, Inc. Announces Annual Meeting Results
    4. Aethlon Medical Announces Data Supported Strategy to Increase Hepatitis-C (HCV) Cure Rates
    5. Halt Medical Presents Strong Results of International Fibroid Studies at National Institutes of Health Global Congress
    6. Medical science helps UK athletes reach peak performance
    7. Rush-Copley Medical Center Selects Pharmacy Xpert from Thomson Reuters to Improve Medication Management
    8. Cephalon Announces Chairman and CEO to Remain on Medical Leave of Absence Indefinitely
    9. Integrated Medical Systems Technology Recognized as Qualified Therapeutic Discovery
    10. Wound Management Technologies to Present at LifeTech Capital Miami Medical Investors Conference
    11. Cardium to Present at the LifeTech Capital Miami Medical Investors Conference
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:10/1/2014)... San Francisco, California (PRWEB) October 01, 2014 ... grant from the National Science Foundation to expand their ... approaches to build and modify DNA. The Small Business ... help commercialize the “j5” technology under exclusive license from ... the Joint BioEnergy Institute , an LBNL laboratory ...
    (Date:10/1/2014)... , October 1, 2014 ... software invited to engage around the theme, ,Commercial Opportunities ...   Elsevier , a ... and services, will host a gathering of some of ... and trends impacting healthcare today and in the future. ...
    (Date:9/30/2014)... This news release is available in German . ... at the Technische Universitt Mnchen (TUM) have demonstrated a ... Their experiments show that future computer chips could be ... transistors. As the main enabling technology of the semiconductor ... fundamental limits, the TUM researchers and collaborators at the ...
    (Date:9/30/2014)... YORK , Sept. 30, 2014 ... and segments with highest potential revenues Do you ... updated report gives you revenue predictions for those ... For those therapies you find financial data, R&D ... analysis you get sales forecasts to 2024 at ...
    Breaking Biology Technology:TeselaGen Receives $750k NSF SBIR Phase II Award 2TeselaGen Receives $750k NSF SBIR Phase II Award 3Elsevier Healthcare and Pharmaceutical Economics Conference 2014 To Convene Industry Leaders to Discuss Top Healthcare Business Issues 2Elsevier Healthcare and Pharmaceutical Economics Conference 2014 To Convene Industry Leaders to Discuss Top Healthcare Business Issues 3A new dimension for integrated circuits: 3-D nanomagnetic logic 2A new dimension for integrated circuits: 3-D nanomagnetic logic 3Biosimilars and Follow-On Biologics: World Industry and Market Prospects 2014-2024 2Biosimilars and Follow-On Biologics: World Industry and Market Prospects 2014-2024 3Biosimilars and Follow-On Biologics: World Industry and Market Prospects 2014-2024 4Biosimilars and Follow-On Biologics: World Industry and Market Prospects 2014-2024 5
    ... made of clay and a bit of high-grade plastic draws oil ... lab tests show that oil absorbed can be squeezed back out ... the material, called an aerogel, believe it will effectively clean up ... and roadways, rivers and oceans. , The EPA estimates that 10 ...
    ... Feb. 4, 2010 -- Four Oak Ridge National Laboratory ... five-year research grants as part of the Department of ... million program, funded under the American Recovery and Reinvestment ... to support exceptional researchers during the crucial early career ...
    ... , , IPSWICH, Mass. ... to the Wellcome Trust Sanger Institute, New England Biolabs is ... England Biolabs as one of its suppliers for next-generation sequencing ... "We are extremely pleased that the Wellcome Trust Sanger Institute, ...
    Cached Biology Technology:New material absorbs, conserves oil 24 ORNL researchers selected for Recovery Act early career funds 24 ORNL researchers selected for Recovery Act early career funds 3Wellcome Trust Sanger Institute to use NEBNext(TM) DNA Sample Preparation Reagents from New England Biolabs for Next Generation Sequencing 2
    (Date:9/30/2014)... do seedless watermelon, salmon, and strawberries all have in ... two sets of chromosomes and are diploid, these organisms ... sets of chromosomesseedless watermelon and salmon have 3 and ... While this might seem surprising, in fact most ... first discovered over a century ago, but only recently, ...
    (Date:9/30/2014)... A team of environmental scientists and engineers, led ... awarded a three-year, $5.25 million grant from the ... Competitive Research to make a direct positive impact ... remediation and disposal of radioactive contaminants. , "Understanding ... adequately dealing with environmental aspects of nuclear technologies ...
    (Date:9/30/2014)... is available in German . ... the most expensive foods in the world. Because they grow ... But the distinctive smell of truffles is not only of ... under the direction of the Goethe University Frankfurt have discovered ... soil bacteria which are trapped inside truffle fruiting bodies. , ...
    Breaking Biology News(10 mins):Gene doubling shapes the world: Instant speciation, biodiversity, and the root of our existence 2Gene doubling shapes the world: Instant speciation, biodiversity, and the root of our existence 3Gene doubling shapes the world: Instant speciation, biodiversity, and the root of our existence 4Researchers get $5.25 million to advance nuclear technologies in South Carolina 2On the trail of the truffle flavor 2
    ... The biggest ever single UK public investment in bioenergy ... main funding agency for the biosciences the Biotechnology ... 27M BBSRC Sustainable Bioenergy Centre has been launched to ... and emerging UK sustainable bioenergy sector and to ...
    ... Switzerland, Jan. 26 SVOX, the leading provider ... the Professional,Speech Processing Group of Siemens AG, according ... speech technology-related IP of Siemens AG developed,over 25 ... more than 60 patent families. The majority of ...
    ... Spring Harbor Laboratory (CSHL) announced today the discovery of ... time, they reported that their discovery suggests the presence ... in which these and possibly other small RNAs are ... project called ENCODE, also provided information concerning the biological ...
    Cached Biology News:Biggest ever public investment in bioenergy to help provide clean, green and sustainable fuels 2SVOX Acquires Speech Processing Unit of Siemens AG, Expands Into Speech Recognition and Speech Dialog 2CSHL scientists find a new class of small RNAs and define its function 2CSHL scientists find a new class of small RNAs and define its function 3
    Request Info...
    Our original highly-purified, robust Taq Polymerase which delivers consistently high yields and minimal background...
    Recombinant DNA polymerase from Thermus aquaticus expressed in E. coli; 5 units/L; 1 tube of 1, 000 units enzyme/tube w/Buffer II and MgCl2...
    Taq DNA Polymerase (T. aquaticus), 4 x 250 units. For PCR and other procedures requiring DNA polymerase activity at elevated temperatures. Category: Nucleotides & Enzymes & Biochemicals, Modifying En...
    Biology Products: